亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Antimicrobial lipopeptides and their uses II

总结: New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. These novel lipopeptide antibiotics have demonstrated superior in vivo efficacy and toxicity overcurrent polymyxin antibiotics.

技术优势: - Novel lipopeptide antibiotics that target multidrug-resistant Gram- negative bacteria
- Greater efficacy and significantly less nephrotoxicity in animal models than currently available Polymyxin B drugs and Colistin
- Potential for administration via intravenous, inhaled or topical routes

详细技术说明: Using their polymyxin drug discovery platform, researchers from the Monash Institute of Pharmaceutical Sciences have identified a series of proprietary Polymyxin analogues that are active against Gram-negative ‘superbugs’.

The Monash researchers have completed in vivo efficacy and toxicity evaluations of the lipopeptide antibiotics in mouse models. When compared with commercially available Polymyxin B and Colistin, the lipopeptide analogues demonstrate improved antibacterial efficacy (Figure 1) and significantly less nephrotoxicity.

其他: Monash University has extensive academic and industrial experience in medicinal chemistry, pharmacokinetics/ pharmacodynamics, and in vitro and in vivo evaluations of antibiotics. Monash seeks a partner to complete advanced IND-enabling preclinical assessment of its lead candidate lipopeptide and to undertake clinical development.

欲了解更多信息，请点击这里